Cantor Fitzgerald Analysts Give Karyopharm Therapeutics Inc. (KPTI) a $18.00 Price Target
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) received a $18.00 price objective from equities research analysts at Cantor Fitzgerald in a note issued to investors on Thursday. The brokerage currently has a “buy” rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 55.31% from the stock’s current price.
A number of other research firms have also recently weighed in on KPTI. Robert W. Baird reaffirmed an “outperform” rating and set a $15.00 price target on shares of Karyopharm Therapeutics in a research note on Tuesday, July 4th. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Thursday, July 6th. Jefferies Group LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, July 14th. BidaskClub cut shares of Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 31st. Finally, Canaccord Genuity set a $18.00 price target on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. Karyopharm Therapeutics has a consensus rating of “Buy” and an average price target of $15.38.
Karyopharm Therapeutics (KPTI) traded up 1.85% during mid-day trading on Thursday, reaching $11.59. 311,357 shares of the company traded hands. The stock’s 50 day moving average price is $10.74 and its 200 day moving average price is $9.91. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63. The firm’s market capitalization is $546.33 million.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. The business’s revenue was down 95.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.84) earnings per share. Equities analysts forecast that Karyopharm Therapeutics will post ($2.67) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/12/cantor-fitzgerald-analysts-give-karyopharm-therapeutics-inc-kpti-a-18-00-price-target.html.
In related news, Director Mansoor Raza Mirza sold 2,882 shares of the stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $11.00, for a total value of $31,702.00. Following the sale, the director now directly owns 2,882 shares of the company’s stock, valued at approximately $31,702. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 10,695 shares of company stock worth $118,950. 14.71% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. boosted its stake in shares of Karyopharm Therapeutics by 4.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock worth $1,111,000 after purchasing an additional 3,762 shares during the last quarter. Palo Alto Investors LLC boosted its stake in shares of Karyopharm Therapeutics by 6.4% during the 1st quarter. Palo Alto Investors LLC now owns 3,406,475 shares of the company’s stock worth $43,739,000 after purchasing an additional 206,079 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Karyopharm Therapeutics by 0.9% during the 1st quarter. Wellington Management Group LLP now owns 5,780,553 shares of the company’s stock worth $74,223,000 after purchasing an additional 54,137 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Karyopharm Therapeutics by 7.8% during the 1st quarter. Geode Capital Management LLC now owns 168,770 shares of the company’s stock worth $2,167,000 after purchasing an additional 12,277 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Karyopharm Therapeutics by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 1,236,762 shares of the company’s stock worth $15,880,000 after purchasing an additional 110,093 shares during the last quarter. 58.97% of the stock is currently owned by institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.